Cepheid Opts Not to Renew Contract with Premier | GenomeWeb

NEW YORK (GenomeWeb) – Cepheid said after the close of the market Wednesday that it has decided not to renew its group purchasing contract with Premier.

The Sunnyvale, Calif.-based molecular diagnostics firm said that its current contract with Premier will end on Sept. 30, 2014. It said that customers can order products through other group purchasing organizations with which the firm has contracted, including Amerinet, Baycare, HPA, MedAssets, Novation, ROi, and HealthTrust, or directly from the firm.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.

In Nature this week: genomic analysis of prehistoric New Mexicans, a nanopore method for mapping DNA methylation, and more.

A new study finds that adding missing good bacteria to the skin microbiome of atopic dermatitis patients decreases Staphylococcus aureus colonization.